Takeda

Global Contract Manufacturing of Pharmaceuticals

Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the EU

Takeda Pharmaceutical Company today announced that a marketing authorisation application (MAA) has been submitted to the European Medicines Agency (EMA) for vedolizumab, an...

Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the EU